Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

64 questions · 64 findings · 5 reviews · Schizophrenia

No studies found 25 · 39.1%GRADE not reported 2 · 3.1%Very low 25 · 39.1%Low 6 · 9.4%Moderate 5 · 7.8%High 1 · 1.6%

FLUPHENAZINE vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Acceptability of treatment ‐ leaving the study early · patients with schizophrenia

FLUPHENAZINE showed no clear difference in acceptability of treatment‐leaving the study early due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).

1 finding from 1 review

FLUPHENAZINE vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Adverse effects ‐ movement disorders ‐ At least one movement disorder · patients with schizophrenia

FLUPHENAZINE may leads to higher adverse effects‐movement disorders‐at least one movement disorder compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).

1 finding from 1 review

FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE

Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · patients with schizophrenia

It is very uncertain whether FLUPHENAZINE DECANAOTE changes extrapyramidal adverse effects ‐ general compared with FLUPHENAZINE ENANTHATE (very low certainty).

1 finding from 1 review

FLUPHENAZINE (ORAL) vs placebo

Global state: Not improved or worsened ‐ medium term Dichotomised Montgomery‐Asberg Depression Rating Scale (MDRS) · patients with schizophrenia

It is very uncertain whether ORAL FLUPHENAZINE changes global state: Not improved or worsened ‐ medium termDichotomised… compared with PLACEBO (very low certainty).

1 finding from 1 review

FLUPHENAZINE (ORAL) vs placebo

Adverse effects: Death ‐ long termOccurrences of death · patients with schizophrenia

ORAL FLUPHENAZINE showed no clear difference in adverse effects: Death ‐ long termOccurrences of death compared with PLACEBO (low certainty).

1 finding from 1 review

FLUPHENAZINE (ORAL) vs placebo

Adverse effects: 2. Extrapyramidal ‐ akathisia · patients with schizophrenia

ORAL FLUPHENAZINE probably leads to higher adverse effects: Extrapyramidal effects (akathisia) ‐ short… compared with PLACEBO (moderate certainty).

1 finding from 1 review

FLUPHENAZINE (ORAL) vs placebo

Adverse effects: extrapyramidal adverse effectsParkinsonism (rigidity) short term (< 3 months) Clinical diagnoses · patients with schizophrenia

ORAL FLUPHENAZINE probably leads to higher adverse effects: Extrapyramidal effects (rigidity) ‐ short… compared with PLACEBO (moderate certainty).

1 finding from 1 review